Nichelle Stigger is one of several advocates participating in Johnson & Johnson Innovative Medicine's 'BeLUNG Here' initiative (Johnson & Johnson)
February 21, 2024 02:28 PM ESTUpdated 05:50 PM
Pharma
Marketing

J&J so­cial me­dia pro­gram aims to add more di­verse voic­es in lung can­cer ad­vo­ca­cy

Beth Snyder Bulik

Senior Editor

J&J is invit­ing un­der­rep­re­sent­ed peo­ple in the lung can­cer com­mu­ni­ty to be­come dig­i­tal ad­vo­cates through its “BeLUNG Here” ini­tia­tive.

Lung can­cer pa­tients and care­givers can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times